- Home
- SPTN vs DNTH Comparison
SPTN vs DNTH Comparison
Compare SPTN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPTN
- DNTH
- Stock Information
- Founded
- SPTN 1917
- DNTH 2015
- Country
- SPTN United States
- DNTH United States
- Employees
- SPTN N/A
- DNTH N/A
- Industry
- SPTN Food Distributors
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- SPTN Consumer Discretionary
- DNTH Health Care
- Exchange
- SPTN Nasdaq
- DNTH Nasdaq
- Market Cap
- SPTN 746.4M
- DNTH 817.5M
- IPO Year
- SPTN N/A
- DNTH N/A
- Fundamental
- Price
- SPTN $21.29
- DNTH $28.00
- Analyst Decision
- SPTN Hold
- DNTH Strong Buy
- Analyst Count
- SPTN 1
- DNTH 8
- Target Price
- SPTN $20.00
- DNTH $45.14
- AVG Volume (30 Days)
- SPTN 252.0K
- DNTH 212.8K
- Earning Date
- SPTN 11-06-2024
- DNTH 11-07-2024
- Dividend Yield
- SPTN 4.08%
- DNTH N/A
- EPS Growth
- SPTN 15.52
- DNTH N/A
- EPS
- SPTN 1.33
- DNTH N/A
- Revenue
- SPTN $9,546,450,000.00
- DNTH $4,118,000.00
- Revenue This Year
- SPTN N/A
- DNTH $41.61
- Revenue Next Year
- SPTN $2.22
- DNTH N/A
- P/E Ratio
- SPTN $16.06
- DNTH N/A
- Revenue Growth
- SPTN N/A
- DNTH 8.57
- 52 Week Low
- SPTN $17.74
- DNTH $6.58
- 52 Week High
- SPTN $24.51
- DNTH $33.77
- Technical
- Relative Strength Index (RSI)
- SPTN 44.18
- DNTH 52.40
- Support Level
- SPTN $21.18
- DNTH $26.99
- Resistance Level
- SPTN $22.73
- DNTH $28.88
- Average True Range (ATR)
- SPTN 0.46
- DNTH 1.50
- MACD
- SPTN -0.12
- DNTH 0.10
- Stochastic Oscillator
- SPTN 7.10
- DNTH 70.35
About SPTN SpartanNash Company
SpartanNash Co is a food solutions company that delivers the ingredients. Its principal business activities include, distributing grocery products to a diverse group of independent and chain retailers, its corporate-owned retail stores, and U.S. military commissaries and exchanges; as well as operating a fresh produce distribution network and the Our Family private label brand. The company operates in two segments: Retail and Wholesale. Majority of the revenue is earned from its Wholesale segment which uses a multi-channel sales approach to distribute national brand and private brand products to independent retailers, national accounts, food service distributors, e-commerce providers, and the Company's corporate owned retail stores.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.